Emcure Pharmaceuticals Q1 FY27 reports 22.8% revenue growth to ₹25,804 million, while PAT jumps 36.2% and EBITDA rises 25.8% in Q1 FY27.
Read MoreGennova Biopharmaceuticals
Emcure Takes Full Ownership of Gennova Biopharmaceuticals, Samit Mehta Named CEO
Gennova Biopharmaceuticals becomes a wholly owned Emcure subsidiary as Samit Mehta takes charge to drive biologics and biosimilars growth.
Read More